TiGenix : to Present at Key Conferences H1 2013
(Thomson Reuters ONE) -
february 4, 2013
TiGenix to Present at Key Conferences
H1 2013
Leuven (BELGIUM) - February 4, 2013 - TiGenix (Euronext Brussels: TIG), a leader
in the field of cell therapy, announced today that during the first half of
2013 the company will present at a number of key events in Europe and the U.S.
geared at investor, industry, and academic audiences to highlight the commercial
potential of ChondroCelect®, the only approved cell therapy in Europe, and of
the company's innovative proprietary allogeneic stem cell platform with programs
in Phase II, and III for respectively the treatment of rheumatoid arthritis
(Cx611) and perianal fistulas in Crohn's disease (Cx601).
February 11-12
BIO CEO Investor Conference, The Waldorf Astoria, New York, NY, U.S.
Presenter: Eduardo Bravo, CEO
Date & time: Tuesday, February 12, 8:30 - 8:55
Room: Room Conrad
Click here for access to live webcast (registration free, but required)
Replay available 1 hour after live event; archived webcast expires May 12, 2013
February 19
8(th) Annual Stem Cell Summit, Battery Gardens, Battery Park, New York, NY, U.S.
Presenter: Eduardo Bravo, CEO
Date & time: Tuesday, February 19, 11:55 - 12:18
March 11-13
BIO-Europe Spring, Centre Convencions Internacional, Barcelona, Spain
Attendees: Eduardo Bravo, CEO, Claudia Jiménez, Senior Director Corporate
Development
March 16
KBC Bolero/Flanders Bio Retail Event, KBC Tower, Ghent, Belgium
Presenter: Eduardo Bravo, CEO
March 19
KBC Healthcare Conference, Brussels, Belgium
Attendees: Eduardo Bravo, CEO, Claudia D'Augusta, CFO
March 23
Dag van de Belegger, KBC Private Banking, Leuven, Belgium
Presenter: Wilfried Dalemans, CTO
Location: Archipel Business Center
Date & time: Saturday, March 23, 11:45 - 12:30
April 15-16
8th edition European Smallcap Event, Paris, France
Attendees: Eduardo Bravo, CEO, Claudia D'Augusta, CFO
April 17
BioCapital, The Grand, Amsterdam, the Netherlands
Presenter: Claudia D'Augusta, CFO
April 17
RegenMed Investor Day, New York, NY, U.S.
Presenter: Eduardo Bravo, CEO
April 22-25
BIO International Convention, McCormick Place, Chicago, Illinois, U.S.
Attendee: Claudia Jimenez, Senior Director Corporate Development
April 23
6(th)Annual Kempen & Co Healthcare Conference, Amsterdam, the Netherlands
Attendee: Claudia D'Augusta, CFO
May 21-23
World Stem Cell & Regenerative Medicine Congress, Victoria Plaza, London, UK.
Presenter: Eduardo Bravo, CEO
Date & time: Tuesday, May 21, 10:05 - 10:30
Title: Commercial financing: exploiting translational funding opportunities
May 22-23
BioEquity Europe 2013, Stockholm, Sweden
Presenter: Eduardo Bravo, CEO
May 30
Knowledge for Growth, ICC Ghent, Belgium
Attendee: Wilfried Dalemans, CTO
For more information:
Eduardo Bravo
Chief Executive Officer
eduardo.bravo(at)tigenix.com
Claudia D'Augusta
Chief Financial Officer
claudia.daugusta(at)tigenix.com
Hans Herklots
hans.herklots(at)tigenix.com
+32 16 39 60 97
About TiGenix
TiGenix NV (Euronext Brussels: TIG) is a leading European cell therapy
company with a marketed product for cartilage repair, ChondroCelect®, and a
strong pipeline with clinical stage allogeneic adult stem cell programs for the
treatment of autoimmune and inflammatory diseases. TiGenix is based out of
Leuven (Belgium) and has operations in Madrid (Spain), and Sittard-Geleen
(the Netherlands). For more information please visit www.tigenix.com.
Forward-looking information
This document may contain forward-looking statements and estimates with respect
to the anticipated future performance of TiGenix and the market in which it
operates. Certain of these statements, forecasts and estimates can be recognised
by the use of words such as, without limitation, "believes", "anticipates",
"expects", "intends", "plans", "seeks", "estimates", "may", "will" and
"continue" and similar expressions. They include all matters that are not
historical facts. Such statements, forecasts and estimates are based on various
assumptions and assessments of known and unknown risks, uncertainties and other
factors, which were deemed reasonable when made but may or may not prove to be
correct. Actual events are difficult to predict and may depend upon factors that
are beyond TiGenix' control. Therefore, actual results, the financial condition,
performance or achievements of TiGenix, or industry results, may turn out to be
materially different from any future results, performance or achievements
expressed or implied by such statements, forecasts and estimates. Given these
uncertainties, no representations are made as to the accuracy or fairness of
such forward-looking statements, forecasts and estimates. Furthermore, forward-
looking statements, forecasts and estimates only speak as of the date of the
publication of this document. TiGenix disclaims any obligation to update any
such forward-looking statement, forecast or estimates to reflect any change in
TiGenix' expectations with regard thereto, or any change in events, conditions
or circumstances on which any such statement, forecast or estimate is based,
except to the extent required by Belgian law.
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: TiGenix via Thomson Reuters ONE
[HUG#1674895]
Unternehmensinformation / Kurzprofil:
Datum: 04.02.2013 - 07:01 Uhr
Sprache: Deutsch
News-ID 225646
Anzahl Zeichen: 6683
contact information:
Town:
Leuven
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 216 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"TiGenix : to Present at Key Conferences H1 2013"
steht unter der journalistisch-redaktionellen Verantwortung von
TiGenix (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
